Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and modera...

por Toth, Peter P., Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Szarek, Michael, Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman C.W., Sweeney, Michael, Ray, Kausik K.
Publicado 2022